Activation of the GLP-1 receptor by a non-peptidic agonist.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
01 2020
Historique:
received: 10 05 2019
accepted: 08 11 2019
pubmed: 10 1 2020
medline: 28 4 2020
entrez: 10 1 2020
Statut: ppublish

Résumé

Class B G-protein-coupled receptors are major targets for the treatment of chronic diseases, including diabetes and obesity

Identifiants

pubmed: 31915381
doi: 10.1038/s41586-019-1902-z
pii: 10.1038/s41586-019-1902-z
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Isoquinolines 0
Pyridines 0
TT-OAD2 0
Phenylalanine 47E5O17Y3R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

432-436

Commentaires et corrections

Type : CommentIn

Références

Bortolato, A. et al. Structure of class B GPCRs: new horizons for drug discovery. Br. J. Pharmacol. 171, 3132–3145 (2014).
pubmed: 24628305 pmcid: 4080969
Liang, Y. L. et al. Cryo-EM structure of the active, G
pubmed: 30209400 pmcid: 6166790
Liang, Y. L. et al. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature 555, 121–125 (2018).
pubmed: 29466332
Liang, Y. L. et al. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546, 118–123 (2017).
pubmed: 28437792 pmcid: 5832441
Zhao, L. H. et al. Structure and dynamics of the active human parathyroid hormone receptor-1. Science 364, 148–153 (2019).
pubmed: 30975883 pmcid: 6929210
Zhang, Y. et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546, 248–253 (2017).
pubmed: 28538729 pmcid: 5587415
Siu, F. Y. et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444–449 (2013).
pubmed: 23863937
Zhang, H. et al. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature 546, 259–264 (2017).
pubmed: 28514451 pmcid: 5492955
Zhang, H. et al. Structure of the glucagon receptor in complex with a glucagon analogue. Nature 553, 106–110 (2018).
pubmed: 29300013
Song, G. et al. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 546, 312–315 (2017).
pubmed: 28514449
Htike, Z. Z. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 19, 524–536 (2017).
pubmed: 27981757
Aroda, V. R. et al. PIONEER 1: Randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes. Diabetes Care 42, dc190749 (2019).
Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394, 39–50 (2019).
pubmed: 31186120
Wootten, D. et al. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83, 822–834 (2013).
pubmed: 23348499
Nolte, W. M. et al. A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat. Chem. Biol. 10, 629–631 (2014).
pubmed: 24997604
Freeman, J. W. S. et al. TTP273: Oral, G protein pathway selective clinical-stage GLP-1 receptor (GLP-1R) agonist. Keystone Symposium, Keystone, CO February 22 http://vtvtherapeutics.com/wp-content/uploads/pdf/GLP1_poster_animation_Keystone_CO_FINAL.pdf (2016).
Chen, D. et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl Acad. Sci. USA 104, 943–948 (2007).
pubmed: 17213311
Jazayeri, A. et al. Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 546, 254–258 (2017).
pubmed: 28562585
Freeman, J. D. C., Dunn, I. & Valcarce, C. TTP273, Oral (nonpeptide) GLP-1R agonist: improved glycemic control without nausea and vomiting in phase 2. American Diabetes Association 77th Scientific Sessions, San Diego, CA, June 9–13, 2017 http://vtvtherapeutics.com/wp-content/uploads/pdf/ADA_Logra_study_results_poster_1220-P%20Final.pdf (2017).
Runge, S., Thøgersen, H., Madsen, K., Lau, J. & Rudolph, R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J. Biol. Chem. 283, 11340–11347 (2008).
pubmed: 18287102
DeVree, B. T. et al. Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535, 182–186 (2016).
pubmed: 27362234 pmcid: 5702553
Yin, Y. et al. An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain. Cell Discov. 2, 16042 (2016).
pubmed: 27917297 pmcid: 5118412
Zhao, L. H. et al. Differential requirement of the extracellular domain in activation of class B G protein-coupled receptors. J. Biol. Chem. 291, 15119–15130 (2016).
pubmed: 27226600 pmcid: 4946928
Ehrenmann, J. et al. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nat. Struct. Mol. Biol. 25, 1086–1092 (2018).
pubmed: 30455434
Yang, L. et al. Conformational states of the full-length glucagon receptor. Nat. Commun. 6, 7859 (2015).
pubmed: 26227798 pmcid: 4532856
Wootten, D., Simms, J., Miller, L. J., Christopoulos, A. & Sexton, P. M. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc. Natl Acad. Sci. USA 110, 5211–5216 (2013).
pubmed: 23479653
dal Maso, E. et al. The molecular control of calcitonin receptor signaling. ACS Pharmacol. Transl. Sci. 2, 31–51 (2019).
Wootten, D. et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165, 1632–1643 (2016).
pubmed: 27315480 pmcid: 4912689
Lei, S. et al. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. J. Biol. Chem. 293, 9370–9387 (2018).
pubmed: 29717000 pmcid: 6005446
Liang, Y.-L. et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharmacol. Transl. Sci. 1, 9 (2018).
Furness, S. G. B. et al. Ligand-dependent modulation of G protein conformation alters drug efficacy. Cell 167, 739–749.e711 (2016).
pubmed: 27720449
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466 pmcid: 28250466
Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
pubmed: 4711343 pmcid: 4711343
Nakane, T., Kimanius, D., Lindahl, E. & Scheres, S. H. Characterisation of molecular motions in cryo-EM single-particle data by multi-body refinement in RELION. eLife 7, e36861 (2018).
pubmed: 29856314 pmcid: 6005684
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
pubmed: 6250425 pmcid: 6250425
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local resolution of cryo-EM density maps. Nat. Methods 11, 63–65 (2014).
pubmed: 24213166
Chan, K. Y., Trabuco, L. G., Schreiner, E. & Schulten, K. Cryo-electron microscopy modeling by the molecular dynamics flexible fitting method. Biopolymers 97, 678–686 (2012).
pubmed: 22696404 pmcid: 3376020
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. D 65, 1074–1080 (2009).
pubmed: 19770504
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 (2018).
Jacobson, M. P. et al. A hierarchical approach to all-atom protein loop prediction. Proteins 55, 351–367 (2004).
pubmed: 15048827
Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics Chapter 5, Unit 5.6 (2006).
pubmed: 18428767
Vohra, S. et al. Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies. J. R. Soc. Interface 10, 20120846 (2012).
pubmed: 23235263
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph 14, 33–38 (1996).
pubmed: 8744570
Rasmussen, S. G. et al. Crystal structure of the β
pubmed: 21772288 pmcid: 3184188
Carpenter, B., Nehmé, R., Warne, T., Leslie, A. G. & Tate, C. G. Structure of the adenosine A
pubmed: 27462812 pmcid: 4979997
Huang, J. & MacKerell, A. D. Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 34, 2135–2145 (2013).
pubmed: 23832629 pmcid: 3800559
Doerr, S., Harvey, M. J., Noé, F. & De Fabritiis, G. HTMD: high-throughput molecular dynamics for molecular discovery. J. Chem. Theory Comput. 12, 1845–1852 (2016).
pubmed: 26949976
Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson–Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665–W667 (2004).
pubmed: 15215472 pmcid: 441519
Olsson, M. H., Søndergaard, C. R., Rostkowski, M. & Jensen, J. H. PROPKA3: consistent treatment of internal and surface residues in empirical pka predictions. J. Chem. Theory Comput. 7, 525–537 (2011).
pubmed: 26596171
Lomize, M. A., Lomize, A. L., Pogozheva, I. D. & Mosberg, H. I. OPM: orientations of proteins in membranes database. Bioinformatics 22, 623–625 (2006).
pubmed: 16397007
Sommer, B. Membrane packing problems: a short review on computational membrane modeling methods and tools. Comput. Struct. Biotechnol. J. 5, e201302014 (2013).
pubmed: 24688707 pmcid: 3962210
Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671–690 (2010).
pubmed: 19575467 pmcid: 2888302
Vanommeslaeghe, K. & MacKerell, A. D. Jr. Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing. J. Chem. Inf. Model. 52, 3144–3154 (2012).
pubmed: 23146088 pmcid: 3528824
Vanommeslaeghe, K., Raman, E. P. & MacKerell, A. D. Jr. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges. J. Chem. Inf. Model. 52, 3155–3168 (2012).
pubmed: 23145473 pmcid: 3528813
Harvey, M. J., Giupponi, G. & Fabritiis, G. D. ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. J. Chem. Theory Comput. 5, 1632–1639 (2009).
pubmed: 26609855
Loncharich, R. J., Brooks, B. R. & Pastor, R. W. Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide. Biopolymers 32, 523–535 (1992).
pubmed: 1515543
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684 (1984).
Kräutler, V. G., van Gunsteren, W. F. & Hünenberger, P. H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501–508 (2001).
Essmann, U. P. & Berkowitz, L. M.L. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577 (1995).
Cuzzolin, A., Deganutti, G., Salmaso, V., Sturlese, M. & Moro, S. AquaMMapS: an alternative tool to monitor the role of water molecules during protein-ligand association. ChemMedChem 13, 522–531 (2018).
pubmed: 29193885
Wall, M. E., Calabró, G., Bayly, C. I., Mobley, D. L. & Warren, G. L. Biomolecular solvation structure revealed by molecular dynamics simulations. J. Am. Chem. Soc. 141, 4711–4720 (2019).
pubmed: 30834751
Koole, C. et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol. Pharmacol. 78, 456–465 (2010).
pubmed: 20547734 pmcid: 3202488
Savage, E. E., Wootten, D., Christopoulos, A., Sexton, P. M. & Furness, S. G. A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. Biotechniques 54, 217–221 (2013).
pubmed: 23581469
Jun, L. S. et al. A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One 9, e93746 (2014).
pubmed: 24695667 pmcid: 3973576

Auteurs

Peishen Zhao (P)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Yi-Lynn Liang (YL)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Matthew J Belousoff (MJ)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Giuseppe Deganutti (G)

School of Biological Sciences, University of Essex, Colchester, UK.

Madeleine M Fletcher (MM)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Francis S Willard (FS)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Michael G Bell (MG)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Michael E Christe (ME)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Kyle W Sloop (KW)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Asuka Inoue (A)

Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.

Tin T Truong (TT)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Lachlan Clydesdale (L)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Sebastian G B Furness (SGB)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Arthur Christopoulos (A)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

Ming-Wei Wang (MW)

The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
School of Pharmacy, Fudan University, Shanghai, China.

Laurence J Miller (LJ)

Mayo Clinic, Scottsdale, AZ, USA.

Christopher A Reynolds (CA)

School of Biological Sciences, University of Essex, Colchester, UK.

Radostin Danev (R)

Graduate School of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan. rado@m.u-tokyo.ac.jp.

Patrick M Sexton (PM)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. patrick.sexton@monash.edu.
School of Pharmacy, Fudan University, Shanghai, China. patrick.sexton@monash.edu.

Denise Wootten (D)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. denise.wootten@monash.edu.
School of Pharmacy, Fudan University, Shanghai, China. denise.wootten@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH